Navigation Links
Interleukin Genetics, Inc. Announces Positive Results from Clinical Study Evaluating Genetic Test's Impact on Weight Loss
Date:9/23/2009

WALTHAM, Mass., Sept. 23 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today top-line positive results from a retrospective clinical study on weight management using patients who participated in a diet study previously reported in the Journal of the American Medical Association. The new clinical study demonstrated that individuals following diets matched to their genotype, as determined by the Interleukin Genetics Weight Management Genetic Test, showed statistically significant greater weight loss and other benefits at all time points (2 months, 6 months and 12 months) when compared to individuals on diets not matched to their genotype.

Study Design

Overweight/obese premenopausal women participated in a one-year weight loss study comparing four weight loss diets: very low carbohydrate, low carbohydrate/high protein, low fat and very low fat. Beginning in 2008, participants who completed the trial were invited by e-mail and postal mail to provide DNA samples by a simple cheek swab. Of those participants, 145 responded. Genotyping was accomplished in 101 Caucasian participants who were categorized using the Interleukin Genetics Weight Management Genetic Test into three pre-determined composite genotype patterns of individuals who are more likely to respond to calorie reduction diets that are: a) low fat, b) low carbohydrate, or c) balanced in macronutrients. The primary endpoint analysis compared weight loss for women who were on a diet that was consistent with their genotype category to those individuals on diets not suitable for their genetic pattern.

Key Data

Highlights from the studies include:

-- Average weight loss of 6.2% (13.2 lbs) was achieved by individuals who were assigned to the genotype appropriate diets for 12 months versus 2.4% (4.6 lbs) for individuals assigned to inappropriate diets (p=0.013);

-- Average percent change in waist circumference of 6.5% (2.6 inches) was achieved by individuals who were assigned to the genotype appropriate diets for 12 months versus 3.2% (1.2 inches) for individuals assigned to inappropriate diets (p=0.01).

"The outstanding results from this study confirm the positive benefit of applying the proper use of genetics in the field of weight management," stated Lewis H. Bender, Chief Executive Officer of Interleukin Genetics. "Our data indicates that choosing a diet based on genetics provides results comparable to the key industry benchmarks for treatment options in the field of obesity. We intend to submit full data for publication as soon as possible, as well as initiate partnering discussions for distribution of our product with appropriate companies focused on weight management."

About the Weight Management Genetic Test

The Interleukin Genetics Weight Management Genetic Test is marketed under the brand name Inherent Health (www.inherenthealth.com) and is a proprietary genetic test panel that analyzes single nucleotide variations among several functional genes to create macronutrient percentage diet and exercise recommendations for the individual. The test involves a simple swab of the cheek that is then sent to Interleukin Genetics' CLIA-certified laboratory for analysis. A detailed report explaining the test results and diet recommendations is provided to individuals within two weeks after sample submission.

About Interleukin Genetics

Interleukin Genetics, Inc. (NYSE Amex: ILI) develops and markets genetic tests that empower consumers to prevent chronic diseases of aging and that assist pharmaceutical companies in the development and marketing of targeted therapeutics. The Company leverages its research, intellectual property and biomarker development experience to facilitate the emerging personalized health market. Interleukin Genetics is headquartered in Waltham, MA. For more information please visit www.ilgenetics.com.

Certain statements contained herein are "forward-looking" statements including statements regarding potential partnerships with weight management companies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the risk of market acceptance of the Company's products, the risk of technology and product obsolescence, delays in product development, the performance of commercial partners, the availability of adequate capital, the actions of competitors and other competitive risks, and those risks and uncertainties described in the Company's annual report on Form 10-K for the year ended December 31, 2008, quarterly reports on Form 10-Q and other filings with the Securities and Exchange Commission. The Company disclaims any obligation or intention to update these forward-looking statements.


'/>"/>
SOURCE Interleukin Genetics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Interleukin Genetics Presents Research Linking Vertebral Fractures to Gene Variations in Asian Women With Osteoporosis
2. Interleukin Genetics and Geisinger to Collaborate on Genetic Tests to Predict Weight Loss Success
3. Interleukin Genetics to Present Important New Findings at 2008 World Congress on Osteoarthritis
4. Interleukin Genetics Wins International Award for Outstanding Research Published in the Journal, Nutrition
5. Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format
6. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
7. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
8. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
9. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
10. Boston University and The Center for Human Genetics, Inc. Announce Change in Testing Services
11. Medivation Announces Initiation of Phase 3 Clinical Trial of MDV3100 in Advanced Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Research and Markets ... Electronics 2015-2025: Applications, Technologies, Forecasts" report to ... In-Mold Electronics, Smart Skin, Structural Health Monitoring, Composite ... Structural electronics involves electronic and/or electrical components and ... dumb structures such as vehicle bodies or conformally ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June ... -based mobile pulmonary function testing company, is now able to ... devices developed by ndd Medical Technologies , Inc. ... done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ... , can get any needed testing done in the comfort of ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The ... published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):